In the case of B cell lymphoma, which encompasses diffuse large B cell lymphoma, mantle cell lymphoma, follicular lymphoma and high grade B cell lymphoma, complete response (CR) rates following treatment with CD19-targeted CD28ζ CAR-T cells range from 53–67% [201,202,205,206,207] and 40–62% for BBζ CAR-T cell products [49,52,197,208,209]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.